CivaTech Oncology — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Total funding raised: $12.5M

Overview

CivaTech Oncology is a commercial-stage company pioneering a new standard in localized radiation therapy through its proprietary polymer-encapsulated brachytherapy sources. Its flagship products, CivaString® and CivaSheet®, are FDA-cleared and NRC-approved for treating a wide range of solid tumors, offering advantages like homogeneous dose distribution, reduced procedure time, and elimination of long-term metal toxicity risks. Founded in 2009 (with roots from 2006), the company is leveraging its unique technology platform to address unmet needs in cancer care, particularly in complex surgical oncology cases like pancreatic and prostate cancer. It operates as a private entity, generating revenue from the sale of its medical devices.

Oncology

Technology Platform

Proprietary polymer-encapsulated source technology for low-dose rate (LDR) brachytherapy, enabling directional, homogeneous radiation delivery with non-metallic, flexible, and bioabsorbable implants.

Funding History

2

Total raised:$12.5M

Series A$10MUndisclosedJun 15, 2018

Seed$2.5MUndisclosedJun 15, 2015

Opportunities

The primary opportunity lies in displacing traditional metallic brachytherapy seeds and other intraoperative radiation techniques with its superior polymer-based, directional devices.

The broad FDA clearance for 'any solid tumor' allows for rapid expansion into multiple high-recurrence cancer types, such as pancreatic and soft tissue sarcoma, where effective local control is a major unmet need.

Risk Factors

Key risks include slow commercial adoption due to physician inertia with existing techniques, the complexity and cost of maintaining dual FDA/NRC regulatory compliance, and challenges in securing adequate insurance reimbursement for its novel products.

Competition from established brachytherapy suppliers and alternative radiation modalities also poses a significant threat.

Competitive Landscape

CivaTech competes with established manufacturers of traditional LDR brachytherapy seeds (e.g., Best Medical International, Elekta/Bebig) and providers of intraoperative radiation therapy (IORT) systems like electron beam devices. Its differentiation is based on its unique polymer encapsulation, directional capability (CivaSheet®), and non-metallic composition, positioning it as a potential niche disruptor rather than a direct, head-to-head competitor with commodity seeds.

More companies in Radiopharmaceuticals →More companies in United States →